MENU
ALXO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
ALX Oncology Holdings (ALXO) Ownership - Who owns ALX Oncology Holdings?
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials... Show more
Profile
Industry
N/A
Address
323 Allerton Avenue
Phone
+1 650 466-7125
Employees
72
Web
https://www.alxoncology.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
28.92M
P/E Ratio
N/A
Total Cash
127.76M
Projected Growth
N/A
Total Debt
9.9M
Revenue
N/A
Risk (Beta)
0.55
Dividend Yield
N/A
Total Cash/Share
2.39
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
ALXO
Capitalization
28.9M
P/E Ratio
N/A
Risk (Beta)
0.55
Dividend Yield
N/A
Total Cash
128M
Total Cash/Share
2.39
Total Debt
9.9M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
114M
P/B Ratio
0.25
Cash Flow
N/A
Earnings
-2.58
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
53K
Current Ratio
7.26
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-132.25M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-69.10
Shares Held By Institutions
87.1M
Shares Outstanding - Current
53.4M
Total Liabilities
34.2M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-67.563
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical stage company, which engages in the research and development of therapies for cancer patients
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
323 Allerton Avenue
Phone
+1 650 466-7125
Employees
72
Web
https://www.alxoncology.com